1. Home
  2. MLYS vs DHC Comparison

MLYS vs DHC Comparison

Compare MLYS & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$28.21

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Logo Diversified Healthcare Trust of Beneficial Interest

DHC

Diversified Healthcare Trust of Beneficial Interest

N/A

Current Price

$7.47

Market Cap

1.8B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
MLYS
DHC
Founded
2019
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.8B
IPO Year
2023
1998

Fundamental Metrics

Financial Performance
Metric
MLYS
DHC
Price
$28.21
$7.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$48.67
$8.00
AVG Volume (30 Days)
841.5K
1.3M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
0.53%
EPS Growth
37.43
23.23
EPS
N/A
N/A
Revenue
N/A
$1,074,819,000.00
Revenue This Year
N/A
$3.13
Revenue Next Year
N/A
$7.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.59
52 Week Low
$22.30
$3.93
52 Week High
$47.65
$9.66

Technical Indicators

Market Signals
Indicator
MLYS
DHC
Relative Strength Index (RSI) 61.44 31.28
Support Level $25.42 $6.92
Resistance Level $31.26 $9.66
Average True Range (ATR) 1.21 0.26
MACD 0.28 -0.03
Stochastic Oscillator 78.88 11.11

Price Performance

Historical Comparison
MLYS
DHC

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.

Share on Social Networks: